Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
59
resultados
Última actualización
17/01/2026 [07:42:00]
Resumen de: US20260016491A1
A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
Resumen de: WO2026015877A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects having, suspected of having, or at risk for developing Alzheimer's disease (AD).
Resumen de: US20260014205A1
Compositions and methods are disclosed herein for the treatment of neurocognitive disorders or central nervous system (CNS) disorders such as Alzheimer's disease (AD) and congenital heart diseases such as hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.
Resumen de: WO2026013413A1
The invention relates to in situ methods for detecting the presence of misfolded proteins in samples (e.g. tissue samples). The invention also relates to the use of said methods in the detection of a proteinopathy or an increased risk thereof in a subject and to methods of determining the efficacy of therapeutic interventions.
Resumen de: WO2026012596A1
The invention relates to a method for diagnosis, disease monitoring and/or therapy guidance in a patient suspected of having a neurodegenerative disease of the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis-spectrum (FTD-ALS-spectrum), comprising (a.) providing a sample obtained from said patient, wherein said sample comprises extracellular vesicles, (b.) determining a level of one or more FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, (c.) wherein the level of the one or more biomarkers is indicative of whether the patient has (and/or allows to distinguish between) a neurodegenerative disease of the FTD-ALS-spectrum comprising a Tau-proteinopathy or a neurodegenerative disease of the FTD-ALS-spectrum comprising a TAR DNA-binding protein 43 (TPD-43)-proteinopathy. The invention further relates to a kit for carrying out the method of the present invention, methods of treating patients identified using the method of the invention, methods of determining said FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, and samples comprising extracellular vesicles and said FTD-ALS-spectrum biomarkers.
Resumen de: AU2024276342A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: US20260007714A1
The present disclosure provides methods of reducing the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury (DILI). The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
Resumen de: US20260009082A1
Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.
Resumen de: WO2026009791A1
Provided is a detection sensitivity-improving method for improving the sensitivity of detection of a protein. The detection sensitivity-improving method, which is used in a method for detecting, by an antigen-antibody reaction, a protein supported by a matrix, includes performing, before the antigen-antibody reaction, a boiling treatment in which the matrix on which the protein is supported is boiled in a sodium sulfate solution to thereby improve the sensitivity of detection of the protein by the antigen-antibody reaction. The protein is an etiological protein of dementia, such as Aβ and Tau. The method can also be applied to the improvement of the sensitivity of detection of a tag protein such as a His tag, an myc tag and a FLAG tag.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US20260009787A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease and hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.
Resumen de: EP4675277A1
The present invention relates to a method for diagnosing or determining the risk of suffering from Alzheimer's disease in a subject, wherein the method comprises determining the level of at least the biomarkers Neurofilament light Chain (NfL), brain-derived neurotrophic factor (BDNF), and tumor growth factor beta 1 (TGF-beta 1) and in addition determining the level of one or more biomarkers selected from the group comprising interleukin 18 (IL-18), Monocyte chemotactic protein-1 (MCP-1), Insulin-like growth factor (IGF) and Vascular endothelial growth factor (VEGF) in a sample of bodily fluid of said subject, calculating a score from the determined biomarker levels, and comparing said score with a reference score, and wherein said subject is diagnosed with Alzheimer's disease, or said subject is determined as having a risk of suffering from Alzheimer's disease, if the score is above said reference score.
Resumen de: MX2025010930A
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US2021132085A1
The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.
Resumen de: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Resumen de: WO2026006441A1
Some embodiments provide for a method for performing a multi-biomarker beta¬ amyloid status determining assay. The method may include: obtaining, for one or more blood or blood-derived samples, values for biomarkers associated with Alzheimer's disease, the values comprising a value for a phosphorylated Tau (p-Tau) and one or more values for one or more additional biomarkers; comparing the value for p-Tau to upper and lower thresholds to determine whether the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold; and after determining that the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold, further interrogating the intermediate range values that are indicative of borderline cases of amyloid pathology using a statistical model to obtain an output facilitating additional classification of the likelihood that the one or more blood or blood-derived samples are associated with a particular beta-amyloid status.
Resumen de: WO2026005695A1
The invention relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to human tau. The monoclonal antibody, or the antigen-binding fragment thereof, can be used in a homogenous immunoassay for the detection and quantification of oligomeric tau and soluble tau aggregates in body fluid samples.
Resumen de: WO2024243435A2
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: US20260002934A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: EP4671765A1
The present disclosure discloses a method, system, composition, and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on spatial transcriptomics of a human hippocampus. In the present disclosure, the rapid and efficient early diagnosis and differential diagnosis of AD-associated cognitive impairment is achieved based on one or more of cholecystokinin (CCK), neurogranin (NRGN), and peripheral myelin protein 2 (PMP2) that are carried by plasma extracellular vesicles (EVs). The present disclosure enables the high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, and demonstrates advantages such as high efficiency and low cost. The present disclosure provides a new technical means and method for the clinical application and large-scale screening related to the accurate diagnosis of AD-associated cognitive impairment.
Resumen de: EP4671757A2
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: US2025389734A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: US2025388967A1
The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Nº publicación: JP2025186346A 23/12/2025
Solicitante:
ヤンセンファーマシューティカエヌ．ベー．
Resumen de: CN120329431A
The present invention provides a method of measuring the amount of mono-or poly-phosphorylated p217 + tau protein in a sample. Also provided are methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of treatment of tauopathies, and methods of determining whether a subject is suitable for anti-p217 + tau antibody therapy. Antibodies for use in the methods and kits comprising the antibodies are also described.
BOPI
Sede Electrónica
